is among the supporting diagnostic criteria in RTT, but recent work has documented increased behavioral responses to potentially painful experiences suggesting there may be a continuum of impaired somatosensory function ranging from sensory gain to loss . The MeCP2 protein is involved in multiple sensory and nociceptive processes. Available evidence from preclinical investigations suggests reflexive pain circuitry is intact but that higher-order discriminatory behavior may be impaired (although motor confounds in the behavioral assays may limit their interpretability). The specific nature of the peripheral sensory neurobiology in RTT patients remains unclear.
Just over 30 years ago, a sural nerve biopsy finding from one RTT case was first reported in which normal myelination was documented (Percy, Zoghbi, & Riccardi, 1985) . A subsequent report on four additional cases from sural and tibial nerve also showed intact myelinated fibers, but a possible relative increase in small unmyelinated axons (Jellinger, Armstrong, Zoghbi, & Percy, 1988) .
Since then, there has been no further clinical investigation of the peripheral nervous system in RTT, particularly with regard to unmyelinated fibers. Recently, however, there have been preclinical observations in a rodent model from the periphery documenting cutaneous hyperinnervation by nonpeptidergic sensory axons (Bhattacherjee et al., 2017) . Based, in part, on this finding, we designed a small clinically based discovery-oriented study to test whether peripheral innervation in patients with RTT would show a similar pattern of hyperinnervation as that observed in the preclinical model. To do so, we leveraged an archived dataset of typical controls to compare against punch skin biopsies with four patients affected by RTT. We hypothesized that the epidermal nerve fiber density (ENFd) values would be different between RTT cases and controls. Given the Bhattacherjee findings were specific to nonpeptidergic fibers, we co-stained for substance P, CCRP, and vasoactive gene-related protein (VIP) and compared fiber counts.
We also explored additional peripheral markers with relevance to somatosensory and nociceptive function.
| ME THODS
Four female patients with RTT were consecutively enrolled from the Rett Syndrome Clinic of Gillette Children's Specialty Healthcare.
Patient 1 was 12 years old with a deletion detected in exon 4 with a novel PSTI fragment of approximately 1.8 kb. She was nonambulatory, gastrostomy (G)-tube dependent, had intractable epilepsy, encephalopathy, chorea, dystonia, dysautonomia, quadriplegia, global developmental impairment, spasticity, seizure disorder, vision impairment, and neuromuscular scoliosis. Patient 2 was 13 years old with a p.Arg168X mutation. She had a seizure disorder, was post spinal fusion for neuromuscular scoliosis, nonambulatory, G-tube dependent, and had laryngotracheomalacia. Patient 3 was 15 years old with a p.Pro272X mutation with comorbid apnea and intractable seizures; she was nonambulatory and G-tube dependent. Patient 4 was 19 years old with a p.Lys144X mutation; she was ambulatory (with assistance), with a seizure disorder, could eat by mouth (no Gtube), and was post spinal fusion.
Following University of Minnesota and Gillette Children's Specialty Healthcare IRB approval and parental consent, single 3 mm punch skin (epidermal) biopsies were obtained from the posteromedial calf and compared with archived normative samples from age-range matched, body-site matched adolescent females without developmental disability (i.e., healthy controls, N = 8, ages 11-17).
For all cases, RTT and controls, biopsies were fixed in Zamboni's solution, cryoprotected, and sectioned with a sliding cryomicrotome.
Antibody diluent and washing solutions were 1% normal donkey serum (NDS) in 0.1 M PBS with 0.3% Triton X-100. Floating sections were blocked with 5% NDS in the diluent solution. Nerve antigens were localized using primary antibodies to protein gene product (PGP) 9.5 (either a rabbit polyclonal or a mouse monoclonal from AbD Serotec), and neuropeptide staining with rabbit primary polyclonal antibodies (from Immunostar) to calcitonin gene-related protein (CGRP), substance P and VIP. Mast cells were labeled with a mouse monoclonal primary antibody to tryptase (from Millipore).
Epidermal keratinocytes and capillaries were labeled with biotinylated Ulex EAE which was secondarily stained with Cy5-labeled streptavidin. Finally, basement membranes between the epidermis and dermis and surrounding capillaries were stained with antibodies to collagen type IV (either a goat polyclonal from Southern Biotech or a mouse monoclonal from Millipore). Primary antibodies were labeled with fluorophore-conjugated (Cy2, Cy3, or Cy5) donkey secondary antibodies (from Jackson ImmunoResearch) directed against the host species used to generate the above primary antibodies. Tissue sections were mounted on coverslips in noble agar, dehydrated in ethanol, cleared in methyl salicylate and mounted in DPX mountant on slides. Epidermal nerve fibers (ENFs) were traced from 16 z-step image stacks (acquired at 2 micron steps with a BX-51
Olympus spinning confocal microscope) using Neurolucida software (MicroBrightField, Colchester, VT) by blinded lab technicians according to established counting criteria and reported as number of ENFs/ mm in a 60-micron thick tissue sections (Kennedy & WendelschaferCrabb, 1993) . for healthy controls.
| RE SULTS
We tested for differences between neuropeptide positive fiber counts for substance P, VIP, and CGRP. There were no statistical differences, on average, between groups on substance P positive or VIP-positive fiber counts. There was a statistically significant difference between the average CGRP-positive fiber counts. The average CGRP-positive fiber count for the RTT samples was 17.8 fibers/3 mm (SD = 3.9) and 11.5 fibers/3 mm (SD = 2.6) for the controls (t 10 = 3.39, p = 0.007).
In addition to the specifically tested ENFd values as per our hypothesis, given reported clinical cutaneous/sensory and autonomic phenotypic features, we investigated Merkel cells (Figure 1 
| D ISCUSS I ON
The Because of the limited sample size, we were not able to meaningfully relate the peripheral neurobiology findings with the clinical presentation of these patients. Future work should align a biobehavioral investigation to characterize cutaneous innervation and neurobiology in relation to thermal, sensory, and pain responsivity at the patient level . (Cook et al., 2015) .
It is well appreciated that
Considering this, abnormal mast cell morphology might not be unexpected and its relation to dendritic cell function and activity should be investigated; but our sample size was too small to make TA B L E 1 Peripheral quantification and immunohistochemistry from RTT 3 mm epidermal punch biopsy for each RTT case and healthy control definitive conclusions and we did not set out to test this relationship. It is also worth noting that MECP2 mutations cause structural changes of brain neurons, often described as more dense and packed (Jentarra et al., 2010) . Recent findings have also documented pronounced changes in sensory olfactory and trigeminal neurons (Degano, Park, Penati, Li, & Ronnett, 2014) providing further evidence of the importance of MeCP2's role in activity-dependent maturation of sensory circuitry. Although speculative, it may be that the complex morphological ENF observations reflect dorsal root ganglion (DRG) neuron abnormalities, as suggested also by Bhattacherjee et al. (2017) in their documented pattern of somatosensory deficits associated with MECP2 mutation, that appear to be cell-autonomous to primary sensory neurons of the DRG. More generally, MeCP2 may play a role in the maturation of peripheral somatosensory circuitry as well. Pacheco et al. (2017) using an RNA sequencing and proteomics approach ("transcriptome-proteome")
showed multiple disrupted pathways and novel "hits" specific to aberrant myelination, inflammation, and vascular disruption.
Overall, with the important caveat that our patient sample was small and one of the clinical convenience, our preliminary observations are in line with recent work on animal models demonstrating peripheral tactile abnormalities in Mecp2-deficient mice (Orefice et al., 2016) and rats (Bhattacherjee et al., 2017) . One notable difference in our clinical observations, however, was the cutaneous hyperinnervation appeared to be primarily a result of proliferation of peptidergic fibers. The significance of that finding for understanding clinical phenotypic sensory features of the disorder and the relation between preclinical models requires careful consideration given that CRGP is a marker for nociceptive dorsal root ganglion (DRG) neurons. Our anecdotal observations of possible differences between RTT patients and controls in arteriole innervation are also consistent with a report regarding microvascular abnormalities in a preclinical RTT model (Panighini et al., 2013) and may provide a new starting place to investigate the pathophysiology underlying one of the cardinal diagnostic features of RTT ("cold hands/cold feet"). A critical next step to improve our scientific understanding of how these peripheral nervous system changes occur (i.e., developmental mechanisms) and their relation to a patient's sensory and autonomic function would necessitate larger samples such that mutation status and patient-specific functioning can be related quantitatively to the biomarker investigation. Doing so would provide the evidence needed to more clearly define critical biobehavioral features of the RTT sensory phenotype and more importantly suggest possible new treatment targets to improve patient outcomes.
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